Therefore, some small molecule inhibitors targeting the NLRP3 inflammasome are potential agents for the treatment of CKD, such as glibenclamide, under clinical application, which has been demonstrated to inhibit CKD and renal fibrosis [105–107]. The gene discussed is NLRP3; the disease is chronic kidney disease.